Alvotech, Dr. Reddy’s ink package to develop biosimilar for cancer treatment

Keytruda (Pembrolizumab) is indicated for the treatment of numerous cancer types. | Photocredit: Wildpixel

The Iceland -based biotech company Alvotech and Dr. Laboratories. Reddy have concluded a collaboration and license agreement to develop, produce and commercialize a biosimilar candidate together to Keytruda (Pembrolizumab) for global markets.

Keytruda (Pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024 the worldwide sale of Keytruda was $ 29.5 billion. The collaboration combines the proven possibilities of Dr. Reddy and Alvotech in biosimilars, which accelerates the development process and the global reach for this Biosimilar candidate is expanded.

According to the conditions of the agreement, the parties will be jointly responsible for the development and production of the Biosimilar candidate and the sharing of costs and responsibilities. Subject to certain exceptions, each party has the right to commercialize the product worldwide.

Production Biosimilars

“We are very delighted to enter into this collaboration for Pembrolizumab with Dr. Reddy’s. This agreement shows the ability of Alvotech to use its special R&D and production platform for biosimilars for biosimilars, which means that the expansion of our pipeline of our pipeline is complied with by a growing world market, said to.

“We are happy to collaborate with alvotech for the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide. Additionally and haas leg and hasbet been bang and haas been bang and haas been bang and hax bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean bean beet bean bean bean bean beet bean bean beet bean bean bean beet bean base be theraporea bean bean bean bean bean beetbet bean bean base beetbet bean bean beetbet bean base be foresty and hax bean bean bean bean bean bean beet bean bean base beetbet bean base be forest. Further Enhance Our Capabilities in Oncology, AS Pembrolizumab Currently Reprontents One of the Most Critical Therapies in Immuno-Oncology, ”Said Erez Israëli, CEO, DR Reddy’s.

Published on June 5, 2025